Update on Biologic Therapy for Pediatric Eosinophilic Esophagitis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease of the esophagus, marked by eosinophilic infiltration, epithelial barrier dysfunction, and fibrosis. Clinical manifestations vary by age, with infants and young children presenting feeding difficulties, vomiting, and failure to thrive, while older children and adults typically exhibit dysphagia, food impaction, and abdominal discomfort. Th2-mediated inflammation, driven by IL-4, IL-5, and IL-13, promotes eosinophil recruitment and activation, leading to tissue damage and development of symptoms. Conventional therapies – including proton pump inhibitors, corticosteroids, elimination diets, and esophageal dilation – are often insufficient, highlighting the need for targeted biologic treatments. This review summarizes the current evidence from pediatric and adult studies. Dupilumab, an IL-4Rα inhibitor, is the only biologic approved for children with EoE, demonstrating high rates of histologic remission, clinical improvement, and a favorable safety profile. Anti-IL-13 agents (cendakimab, dectrekumab) and anti-IL-5/IL-5Rα agents (reslizumab, mepolizumab, benralizumab) effectively reduce eosinophilic infiltration, though symptomatic benefit, particularly for dysphagia, is variable. Other investigational therapies, including lirentelimab, omalizumab, and etrasimod, show promise, while evidence for vedolizumab, natalizumab, and infliximab remains limited. Biologic therapies offer a novel, targeted approach for pediatric EoE, especially in refractory cases, although further studies are needed to optimize clinical efficacy and long-term safety.
Fields of Study & Subjects
Eosinophilic Esophagitis
Asthma and respiratory diseases
Food Allergy and Anaphylaxis Research
Publication details
- Journal / source
- Rivista di immunologia ed allergologia pediatrica.
- Volume
- 39
- Issue
- 4
- Pages
- 63–68
- Publication date
- 1 January 2026
- Language
- EN